Cartesian Therapeutics, Inc. (RNAC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cartesian Therapeutics, Inc. (RNAC) closed at USD 6.34 on 2026-10-14, a change of -23.8 % over the past year, with a market capitalization of USD 199.08M.

Cartesian Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cartesian Therapeutics, Inc. key figures

Previous close

USD 6.34 (2026-10-14)

1-year change

-23.8 %

Market cap

USD 199.08M

Enterprise value

USD 115.33M

P/E ratio (trailing)

-1.14

P/E ratio (forward)

-1.73

EPS (trailing)

-5.78

EPS (forward)

-3.81

PEG ratio

n/a

Price to book

-1.58

Revenue growth

n/a

Earnings growth

-8 %

Dividend per share (trailing)

0.00

Short ratio

14.59

Employees

75

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cartesian Therapeutics, Inc. and compare it with other stocks.